Fluocinolone acetonide (FA) extended release(Eclipse Life Sciences)

Tier C — Watch / trade

Eclipse Life Sciences Inc

Originator

First approval

Expiry (public)

No sales data

Peak sales

Small molecule

Type

Targets：GR

Indications (approved)：Diabetic macular oedema

Regional status

Phase II

2024-08-19

China

Japan

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Fluocinolone acetonide (FA) extended release(Eclipse Life Sciences)?

Approved indications include: Diabetic macular oedema.

When does the Fluocinolone acetonide (FA) extended release(Eclipse Life Sciences) patent expire?

No public expiry year is available for Fluocinolone acetonide (FA) extended release(Eclipse Life Sciences) yet; this page updates once verified.

How do I get a quote for Fluocinolone acetonide (FA) extended release(Eclipse Life Sciences) intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-10-01